2024 Digital Health New Quality Productivity Innovation Cases Announced: Showcasing Breakthrough Applications and Technologies

Case Name:Personalized Brain Function Modulation for Diagnosis and Treatment

Selected Institutions:Beijing Galaxy Fangyuan Technology Co., Ltd.

Application Subfields/Departments/Diseases:Treatment of Brain Diseases

Annual Innovation Achievements and Outcomes:

Due to limited understanding of human brain functional networks and disease-related neural circuits, effective treatments for brain disorders are generally lacking. The personalized Brain Functional Segmentation (pBFS) technology can finely parcellate the brains of different individuals into 213 functionally distinct regions with clear boundaries and precise definitions, helping doctors and scientists understand the functional circuit mechanisms underlying brain disorders, thereby improving the efficacy of treatment.

Galaxy Fangyuan Group’s personalized brain function modulation diagnostic and therapeutic protocol is grounded in the fundamental mechanisms of the brain. Leveraging pBFS technology, it investigates functional circuits associated with brain disorders to formulate individualized brain circuit modulation plans for patients. By employing safe, non-invasive physical intervention methods for brain circuit modulation, the protocol aims to ameliorate brain disorders. Through clinical trials and applications conducted in collaboration with dozens of renowned hospitals across China, the personalized brain function modulation diagnostic and therapeutic protocol has demonstrated favorable outcomes. It currently covers 16 types of brain disorders, including autism spectrum disorder (autism), Parkinson’s disease, post-stroke aphasia/hemiplegia, and depression/anxiety disorders. The protocol spans the departments of neurology, rehabilitation medicine, psychiatry, and pediatrics, providing precise, safe, and personalized treatment solutions for hundreds of millions of brain disorder patients worldwide. Over the past three years, nearly 2,000 patients have been treated, with an overall effective rate exceeding 60%.

This treatment regimen offers three key advantages: first, its breakthrough nature, demonstrating significant efficacy in numerous brain disorders that previously lacked effective therapeutic options; second, its non-invasive safety profile, which allows for broader patient applicability with minimal side effects; and third, its individualized precision, achieving true precision medicine through the development of personalized treatment plans.

Case Name:Alambel Corporate Executive Digital Health Management Services

Selected Institutions:Chengdu Gaoxin Xiangnanli Alanbell Clinic Co., Ltd.

Application Subfields/Departments/Diseases:Medical Services, Digital Health, Health Management

Annual Innovation Achievements and Results:

Through extensive literature review and research, experts at the Alanbell Medical Department have established a relatively unique and effective system for disease prevention and scientific anti-aging, advocating a three-step progressive health coaching philosophy known as the “3B” concept. The three Bs stand for BASIC, BETTER, and BEST.

During the management period, a five-in-one health management team is assigned to each executive. Using the digital mall and Enterprise WeChat as the primary communication channels, the team provides N-to-1 comprehensive, accompanied management services. This enables executives to monitor changes in their health indicators anytime and anywhere, and to timely adjust their health status through online consultations and management.

Leveraging AI algorithms and integrating Alanbell Labs’ globally patented specialized testing technology, this remote medical service model enables fully online testing, result retrieval, report interpretation, and intervention guidance. It aims to achieve precise health management with broader coverage, lower costs, and higher efficiency, targeting customers across China and even globally.

Case Name:Application and Effectiveness Analysis of the AI-Enabled, Companion-Based “Three-Physician Co-Management” Lifestyle Intervention Model in Obesity Prevention and Control

Selected Institutions:Guangzhou Nanda Fit Medical Health Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Chronic Disease Management and Weight Loss

Annual Innovation Achievements and Outcomes:

Nanda Feite, as a pioneer in the field of medical weight management and diabetes management in China, is committed to leveraging cutting-edge medical artificial intelligence and new quality productive forces to build a leading digital healthcare platform for chronic disease management in China. The company adopts an AI-enabled, companionship-based "Three-Physician Co-Management" model. By integrating its self-developed AI agent, "Tangdou," from the application end to the management backend, it achieves automated workflows, providing standardized and highly efficient lifestyle intervention services for patients with overweight/obesity and related complications. This model not only enables large-scale, high-quality delivery of chronic disease management services but also effectively reduces costs, thereby achieving inclusive and accessible care.

The company has cumulatively helped over 30,000 patients successfully achieve weight and fat loss, maintain stable blood glucose levels, and significantly improve chronic disease indicators, thereby demonstrating its remarkable efficacy in weight management and enhancing patient health outcomes through practical case studies. Nanjing FitTech has established collaborative partnerships with more than 40 Grade-A tertiary hospitals in Guangdong Province, Jiangsu Province, and Shanghai, as well as with institutions such as JD Health and Meinian Onehealth, in areas including obesity management models, service implementation, and technical support. These collaborations enable the provision of personalized lifestyle intervention plans, complementary products, and online follow-up services for patients at home.

In addition, Nanda Feite organizes nearly 100 free clinic sessions, 20 large-scale academic symposiums, and close to 100 patient education programs and live-streamed classes annually, dedicated to improving awareness and treatment rates for obesity and diabetes. By virtue of its outstanding achievements, the company has been consecutively recognized as one of the Top 50 Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area, has received the High-Tech Enterprise certification twice, and was honored at the China Innovation and Entrepreneurship Competition in 2023.AIGCTop 20 Healthcare Enterprise, Selected as an Outstanding Case Study in Weight Management by the National Center for Chronic and Noncommunicable Disease Control and Prevention of the Chinese Center for Disease Control and Prevention (2024), Fully Demonstrating Its Professional Expertise and Innovative Capabilities in the Field of Chronic Disease Management.

Case Name:Construction of a Myopia Prevention and Control System Based on Ocular Biometric Big Data

Selected Institutions:Hainan Provincial Eye Hospital

Collaborating Institutions:12mm Health Technology (Hainan) Co., Ltd.

Application Subfields/Departments/Diseases:Myopia Prevention and Control in Adolescents

Annual Innovation Achievements and Outcomes:

Hainan Eye Hospital, in collaboration with Twelve Millimeters Health Technology (Hainan) Co., Ltd., achieved significant progress and innovative outcomes in 2024 with their jointly developed “Myopia Prevention and Control System Based on Ocular Biometric Big Data.” Centered on innovative digital therapeutics, this system breaks through the limitations of traditional myopia prevention and control methods by collecting data on children’s eye-use behaviors and environmental factors via smart wearable devices, integrated with the hospital’s established Electronic Medical Records (EMR) andPACS System, achieving digitalization and personalization in myopia prevention and control.This product marks the first application of digital therapeutics in the field of myopia prevention and control, establishing a closed-loop digital diagnosis and treatment system that encompasses monitoring, analysis, and intervention. It facilitates a paradigm shift in myopia management from merely controlling progression to preventing onset. By leveraging artificial intelligence to assist physicians with analysis and decision-making, the system significantly enhances work efficiency. Furthermore, through Internet of Things (IoT) technology, it enables the decentralization of high-quality medical services to primary care settings, thereby building a specialized medical consortium for myopia prevention and control.

The myopia risk factor monitor received its classification determination on March 27, 2024, becoming the first medical-grade product of its kind both domestically and internationally. The EMR (Electronic Medical Record) and PACS systems established in the hospital’s optometry and refractive surgery departments were put into clinical use on June 11, 2024, serving over 100 outpatients daily. Related products are currently applying for a series of patents and software copyrights, some of which have already been approved. The implementation of this case has not only improved the efficiency and quality of medical services but also provided a novel solution for myopia prevention and control among adolescents, demonstrating significant social value and market potential.

Case Name:Intelligent Clinical Research and Digital Therapeutics Translation Platform (Slan-Bot)^®)

Selected Institutions:Hangzhou Zhilan Health Co., Ltd.

Application Subfields/Departments/Disease Types:Clinical research, such as investigator-initiated trials (IITs), real-world studies (RWS), and patient follow-ups, along with the rapid translation of scientific achievements including digital therapeutics

Annual Innovation Performance and Achievements:

Intelligent Clinical Research and Digital Therapeutics Translation Platform (Slan-Bot)^®) is a patient-centric, data- and AI-driven platform for medical research and digital therapeutics translation, independently developed by Zhilan Health. It serves as the foundational support for cultivating new quality productive forces in digital healthcare, accelerates the layout of digital health concept validation centers, and builds a critical bridge for translating scientific and technological achievements from the laboratory to pilot testing and commercialization. The platform innovatively integrates intelligent digital research with digital interventions. Leveraging extensive corpora and disease models, it supports the rapid assembly of intervention modules through low-code development to construct digital disease intervention solutions, thereby facilitating the seamless connection between medical research and proactive digital therapeutics products.

Slan-Bot^®The platform has been deployed in Southwest, East, and South China as the official underlying technological infrastructure for clinical research and digital health proof-of-concept initiatives. It supports a wide range of disease research and digital intervention services, including disease screening, cohort studies, regional diseases, occupational diseases, and common chronic conditions. Furthermore, it collaborates with multiple Grade A tertiary hospitals on hospital-wide intelligent scientific research and the translational implementation of digital therapeutics.

Case Name:"High-Quality Hospital Development: 'Data-Driven Proactive Blood Glucose Management Practice Across the Entire Hospital'"

Selected Institutions:Sinocare Inc. (300298)

Application Subfields/Departments/Diseases:Chronic Disease Management, Department of Endocrinology

Annual Innovation Achievements and Results:

To enhance the management of diabetic patients in hospitals, Sinocare has established an endocrinology-led proactive diabetes consultation system. This system comprises advanced hardware, such as continuous glucose monitoring (CGM) systems and smart blood glucose meters, and integrates modules for CGM, blood glucose monitoring (BGM), insulin pumps, and patient education. The system seamlessly interfaces with hospital information systems, including HIS, LIS, and EMR. It automatically identifies patients with abnormal blood glucose levels through intelligent screening mechanisms and notifies the attending physicians. With comprehensive acquisition and real-time updates of patient data, a professional endocrinology team provides unified management and close monitoring. Furthermore, leveraging the DPM platform, the system delivers comprehensive whole-course health management services for diabetes, both in-hospital and out-of-hospital, extending beyond diabetes remission.

Key innovations of the system include integrated hardware-software synergy, an intelligent screening and automated notification system, and the concept of virtual ward management. Its prominent advantages encompass comprehensive data integration capabilities, efficient healthcare collaboration mechanisms, and enhanced patient engagement. The system has improved blood glucose target achievement and management rates, reduced the average length of stay for patients, elevated hospital service quality, and fostered mutual benefits for other departments, such as non-endocrinology units. Addressing the frequent occurrence of hyperglycemia among hospitalized patients and the inefficiency of in-hospital consultations, this system leverages informational and intelligent technologies to implement endocrinology-led, hospital-wide blood glucose management, thereby improving medical quality and reducing doctor-patient disputes.

Case Name:Construction of Next-Generation Intelligent Specialty Centers for Parkinson’s Disease

Selected Institutions:Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Collaborating Organizations:Shenzhen Zhenluo Technology Co., Ltd.

Application Subfields/Departments/Diseases:Neuroscience, Parkinson's Disease

Annual Innovation Achievements and Outcomes:

In April 2020, China’s first one-stop diagnosis and treatment center for Parkinson’s disease was established at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Ruijin Hospital and Zhenluo Science jointly built a model “Next-Generation Intelligent Specialty Center for Parkinson’s Disease” and demonstrated its applications. By integrating classic diagnostic and therapeutic techniques with cutting-edge artificial intelligence and digital technologies, the “Next-Generation Intelligent Specialty Center for Parkinson’s Disease” has implemented intelligent clinical workflows—including in-hospital pre-consultation, laboratory and imaging tests, intelligent symptom assessment, and visualized consultations—as well as intelligent management models featuring continuous out-of-hospital quantitative monitoring, periodic quantitative assessments, effective doctor-patient interaction, and dynamic optimization of treatment efficacy. This initiative marked the world’s first implementation of a comprehensive spatiotemporal diagnosis and treatment system and model for Parkinson’s disease, truly realizing a broad-sense one-stop service covering “all times, all spaces, and the entire disease course,” namely the “Next-Generation Intelligent Specialty Center for Parkinson’s Disease.” Based on this application demonstration and related innovative technologies, the team from Ruijin Hospital and Zhenluo Science has published a series of high-quality papers (including multiple articles in top-tier journals) in internationally influential magazines, generating robust clinical evidence. Furthermore, they have collaborated with several leading hospitals across China to conduct prospective multicenter clinical studies. Currently, these concepts have empowered more than 90% of specialized Parkinson’s disease centers in China.

Case Name:Lianxin Smart Operating Room Integrated Solution

Selected Institutions:Shenzhen Linknew Mobile Healthcare Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Smart Operating Room

Annual Innovation Achievements and Outcomes:

The Union New Smart Operating Room Integrated Solution is a modern smart operating room system centered on surgical procedures, aiming to enhance surgical quality and increase operational efficiency while covering the entire perioperative process. The solution comprises one platform, four major product lines, over 40 types of intelligent terminal hardware, and 15 software systems. It focuses on the clinical business processes throughout the perioperative period, implementing refined management of personnel, materials, equipment, workflows, environments, and other aspects. By controlling the surgical process, standardizing perioperative medical practices, ensuring surgical safety, and reducing surgical risks, it promotes standardized surgical operations through improved visualization and operational precision, ultimately delivering better clinical outcomes for patients.

Built on medical Internet of Things (IoT) technology, anchored to the surgical timeline, and centered on patient medical data, this solution provides end-to-end integration across the entire surgical workflow. It seamlessly incorporates smart ward systems to enable unified management of preoperative, intraoperative, and postoperative processes, comprehensively digitizes and centrally archives records of the surgical procedure, supplies data for clinical case studies, reduces medical errors, and thereby enhances operating room efficiency and the quality of medical services.

Case Name:WeDoctor Hainan Dongfang Digital Therapeutics Innovation Project

Selected Institutions:WeDoctor Group

Application Subfields/Departments/Diseases:Chronic Disease Health Management

Annual Innovation Achievements and Results:

WeDoctor’s Hainan Dongfang Digital Therapeutics Innovation Project has broken down information barriers by establishing an interconnected smart platform, setting up chronic disease management centers and standardized chronic disease management clinics, and driving process reengineering through digitalization. It has developed standardized management pathways integrating medical care and prevention, while also forming a team of health managers operating in an “online + offline” model. The project has upgraded the “3+1+N” grid-based service system. As of July 2024, the chronic disease management centers operating at Dongfang People’s Hospital and Gancheng Town Central Health Center had cumulatively managed 6,068 patients with hypertension and diabetes, completed 1,751 individualized management plans, and conducted complication screening for 1,126 patients. This initiative has addressed the shortage of non-clinical support staff in primary healthcare institutions and improved patient satisfaction. Through the joint efforts of health managers and physicians, key performance indicators for disease management have significantly improved, yielding substantial management outcomes.

Case Name:Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: Integrated Data Governance Middle Platform Project

Selected Institutions:Yidu Tech（2158.HK）

Partner Organizations:Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Application Subfields/Departments/Disease Types:Smart Hospital

Annual Innovation Achievements and Outcomes:

The Integrated Data Governance Middle Platform Project at Union Hospital, Tongji Medical College of Huazhong University of Science and Technology is a key initiative driven by policy mandates and oriented toward digital transformation. It aims to comprehensively enhance the hospital’s informatization level, lean management capabilities, and smart hospital construction. The core objective is to establish a high-quality data asset system by setting up data governance organizational frameworks and data standard systems, implementing data quality control, optimizing data collection and processing workflows, and continuously improving specific data governance targets. The development of this platform marks a significant milestone in the hospital’s digital transformation. Leveraging cutting-edge technologies such as big data and artificial intelligence, Yidu Tech has helped build a hospital-wide data middle platform that covers all domains of hospital data. This platform achieves unified data collection, governance, management, and services for both historical and incremental data across clinical care, medical management, and operational management domains. By standardizing and structuring data, it creates a reusable and computable standardized data layer, and establishes a data asset platform, a research data platform, an operational metrics middle platform, and a data openness platform. Medical staff, the Information Department, and third-party vendors can independently perform data queries, dataset construction, data invocation, visual analysis and mining, and data reporting on the platform, thereby improving data usage efficiency and ensuring security and compliance, ultimately promoting the hospital’s digital transformation.

Case Name:Construction of a Demonstration System for Standardized Liver Disease Data Centers

Selected Institutions:Zhejiang Huzhou Huazhuo Information Technology Co., Ltd.

Collaborating Organizations:Shulan (Hangzhou) Hospital Co., Ltd.

Application Subfields/Departments/Diseases:Liver Disease Diagnosis and Treatment, Scientific Research, and Public Health

Annual Innovation Achievements and Outcomes:

The Standardized Liver Disease Data Center, jointly established by Huazhuo Technology and Shulan (Hangzhou) Hospital, is primarily applied in the fields of liver disease diagnosis and treatment, scientific research, and public health. By establishing a scientific liver disease prediction system, data aggregation, standardized processing, and a comprehensive, multi-dimensional platform for collaborative research, it provides high-quality data support to medical institutions, research organizations, and public health departments. This enables more precise and personalized treatment plans for patients and promotes the digitalization and intelligent transformation of liver disease healthcare services. Its core construction focuses on unified data modeling, collection, governance, development, management, and service, thereby facilitating the circulation and application of liver disease medical data elements.

The Standardized Liver Disease Data Center leverages data model-based prediction and diagnosis/treatment, integrating evidence-based medicine with emerging technologies to provide an evidence base for the diagnosis and management of liver diseases. This approach significantly enhances the standards of diagnosis, treatment, and monitoring, thereby reducing rates of missed and misdiagnoses. Through intelligent management, the center enables comprehensive tracking and management of the entire disease course for liver disease patients, improving therapeutic outcomes and quality of life. To date, the Standardized Liver Disease Data Center has managed nearly 60,000 cases of liver disease, with hepatitis B virus (HBV) infections accounting for approximately one-sixth of these cases. This has effectively reduced the risk of cirrhosis and hepatocellular carcinoma, conserving medical resources and lowering healthcare costs. Furthermore, in addition to providing systematic tools, the center empowers partner institutions through multi-dimensional support, including inviting top-tier expert teams to assist with personnel training, advanced studies, ward rounds, and consultations, thereby enhancing clinical capabilities and research proficiency. Currently, the center’s initiatives have helped Zhengzhou Third People’s Hospital achieve a case closure rate of over 80% and Shulan (Hangzhou) Hospital achieve a follow-up rate of over 90%.

Case Name:Application of Digital Enhanced Recovery After Surgery (ERAS) Products in the Perioperative Period for Early-Stage Lung Cancer

Selected Institutions:Zhongxi Medical Technology (Wuxi) Co., Ltd.

Partner Organizations:The First Affiliated Hospital, Zhejiang University School of Medicine

Application Subfields/Departments/Disease Types:Thoracic Surgery

Annual Innovation Achievements and Outcomes:

Current routine postoperative management for patients with early-stage lung cancer lacks effective interventions. Although enhanced recovery protocols are beneficial, they increase the clinical workload and are insufficient in terms of intervention and rehabilitation guidance. Therefore, developing an effective remote intervention management model holds clinical significance.

Zhongxi’s digital therapeutics technology integrates multidisciplinary expert knowledge with patient data to develop deep learning models, thereby generating personalized management plans. Its value lies in enhancing the effectiveness and efficiency of out-of-hospital management, freeing up clinical resources, and improving the quality and standardization of therapeutic management. In prospective clinical studies, Zhongxi’s solution demonstrated post-discharge management outcomes non-inferior to those achieved by multidisciplinary manual management. These groundbreaking findings were presented at the 2024 World Conference on Lung Cancer.

This product can also be integrated with medical-grade home monitoring devices, enabling interconnectivity and in-depth analysis through IoT data to accelerate patients’ pulmonary function recovery, reduce postoperative complications, and support timely and effective post-discharge interventions. It not only meets the needs of top-tier hospitals but also provides best practices that exceed existing capabilities for prefecture-level and county-level hospitals, thereby enhancing their diagnostic and treatment capacities. Currently, the product has been deployed to support the construction of a digital ERAS (Enhanced Recovery After Surgery) management model within Zhejiang Province’s Major Disease Diagnosis and Treatment Platform, extending its impact to multiple ERAS demonstration centers across the province.

Case Name:Machine Learning-Based Digital Rehabilitation Therapy for Autism

Selected Institutions:Beijing Asou Aba Technology Co., Ltd.

Application Subfields/Departments/Diseases:Digital Therapeutics, Department of Pediatric Rehabilitation, Department of Child Healthcare, Department of Developmental and Behavioral Pediatrics, Autism Spectrum Disorder, Developmental Delay

Annual Innovation Performance and Achievements:

The machine learning-based digital therapeutic for autism spectrum disorder (ASD) has had its safety and efficacy scientifically validated by an expert team from the Child Mental Health Center of Peking University Sixth Hospital. As the first ASD digital therapeutic product in China to achieve large-scale commercial sales, it generated over RMB 10 million in revenue during its first quarter on the market. Since July 2023, it has been providing daily supplemental home-based digital rehabilitation services of a specified duration to children undergoing training at the Hainan Provincial Women and Children’s Medical Center Rehabilitation Center. The attrition rate after four months was 4.85%, demonstrating excellent adherence. Notably, as part of the “Hainan Province Digital Therapeutic Intervention Project for Children Aged 0–6 with Autism,” a key livelihood initiative by the Hainan Provincial Government, the product provides digital therapeutic services to 1,016 children under six years of age with ASD across 14 hospitals and three designated institutions of the Disabled Persons’ Federation in eight cities/counties of Hainan Province. Within this project, the monthly attrition rate reached as low as 4.21%, the monthly completion rate stood at 130.69%, and the average daily usage time per patient was 33.16 minutes, yielding significant benefits.

This case innovatively leverages cutting-edge AI technologies, including natural language processing and user recommendation algorithms. Based on a fully independent intellectual property portfolio and an empirically validated online assessment and intervention system, it utilizes nearly 390,000 data points on developmental milestones of children with special needs, over 90 million pediatric rehabilitation records accumulated from offline empirical centers, intervention instruction texts and voice data, interactive texts, behavioral interaction videos, as well as materials related to projects, levels, and scenarios. It constructs a knowledge graph for autism cognitive ability and social skills intervention programs. By integrating patient user profiles and behavioral characteristics, the model is trained to recommend intervention programs along the shortest path. It dynamically generates digital scenarios matched to the intervention programs and digital objects aligned with these scenarios. Furthermore, it generates instructional and interactive speech based on the emotional features extracted from patients’ voice feedback, thereby conducting cognitive ability interventions and providing life-like, immersive social skills training within intervention contexts. This approach enhances adherence and improves the overall efficacy of the intervention.

Case Name:Shukangshi

Selected Institutions:Beijing Yiyue Technology Co., Ltd.

Collaborating Organizations:Peking University Third Hospital

Application Subfields/Departments/Diseases:Orthopedics, Sports Medicine, Rehabilitation

Annual Innovation Achievements and Outcomes:

Shukangshi builds a full-process rehabilitation ecosystem that spans multiple scenarios, including hospital outpatient clinics, inpatient treatment wards, and home-based rehabilitation. Through four core modules—assessment, prescription, AI-guided training, and remote rehabilitation—it achieves seamless integration between in-hospital and out-of-hospital care. Patients can choose to train either within or outside the hospital under the guidance of physicians and AI, while doctors can leverage AI decision trees to remotely adjust rehabilitation plans.

Shukangshi’s self-developed multimodal radar and 3D vision fusion sensor enables high-precision patient assessment and training guidance. Its accuracy and convenience surpass those of traditional sensor products, providing comprehensive rehabilitation solutions. Shukangshi helps bridge the gap in rehabilitation resources by addressing shortages of rehabilitation personnel and hospital beds, thereby elevating the standard of care and allowing primary-care hospitals to deliver tertiary-level rehabilitation services. Personalized treatment plans and intelligent tools make remote rehabilitation feasible. The “AI + Remote Rehabilitation” model improves rehabilitation conditions for patients in remote areas and reduces the need for frequent hospital visits. It shortens outpatient prescription times, optimizes inpatient rehabilitation plans, and enhances overall rehabilitation service capacity. Shukangshi has been validated in nearly 5,000 cases at Peking University Third Hospital and is deployed in more than 100 hospitals across China, having earned multiple software copyrights, patents, and awards.

Case Name:Digital Therapeutics-Based Inhalation Therapy Management Solution

Selected Institutions:Orange Family Technology (Tianjin) Co., Ltd.

Application Subfields/Departments/Disease Types:Chronic Diseases, Respiratory Medicine, Chronic Obstructive Pulmonary Disease (COPD), Asthma

Annual Innovation Achievements and Results:

Digital Therapy-Based Inhalation Treatment Management SolutionOfficially launched in 2022, this solution follows the GOLD-recommended pathway of “treatment monitoring – review and assessment – treatment adjustment.” Driven by software programs, it enables physicians to comprehensively manage patients’ inhalation medication processes both in-hospital and out-of-hospital. Focusing on key technical aspects such as inspiratory capacity assessment/training, inhalation technique evaluation/training, and adherence management for inhalation therapy, the solution innovatively applies a digital therapy system. By integrating inhalation resistance simulation devices, Internet of Things (IoT) technology, large language AI models, and micro-airflow sensing smart hardware, it enhances the efficacy of inhalation treatment, significantly improves patients’ quality of life, and reduces the frequency of acute exacerbations. It serves as an effective tool for managing patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Moreover, it is currently the only solution that truly enables home-based medication management for patients with chronic respiratory diseases (predominantly the elderly) without relying on smartphones.

Digital Therapy-Based Inhalation Treatment Management Solution: The current specific product has obtained the medical device registration certificate as the world’s only digital therapy for inhalation treatment. The scope of application specified in the registration certificate explicitly states that it is designed to “assist clinicians in analyzing patients’ respiratory capacity, help physicians guide patients in selecting appropriate inhalation devices and medications, and collect and analyze respiratory data in real time during medication inhalation, thereby enabling healthcare professionals to monitor patients’ respiratory status and capacity in real time.” It is currently being used clinically at leading national and regional hospitals across China, including China-Japan Friendship Hospital, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, West China Hospital of Sichuan University, Xiangya Second Hospital of Central South University, and Henan Provincial People’s Hospital.

Case Name:Boshi Zeus Smart Minimally Invasive Surgical Platform

Selected Institutions:Guangzhou Baishi Medical Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Minimally Invasive Specialty

Annual Innovation Achievements and Outcomes:

The “Zeus” intelligent minimally invasive surgical platform, independently developed by Baishi Medical, comprises several subsystems: digital twin-based 3D reconstruction and segmentation, surgical planning, real-time multimodal fusion of imaging and optical holography, 3D visualization with real-time localization and navigation, and digitally assisted instrument therapy. Guided by the core principles of “digitalization, precision, and standardization,” Baishi Zeus creates a new-generation innovative ecosystem for minimally invasive treatment. It empowers the minimally invasive therapy industry and various clinical subspecialties, enhances the efficiency and overall benefits of medical resource utilization, promotes equity and quality in healthcare services, and makes surgical treatments more accessible, efficient, and safer.

Taking the iLocate Spine minimally invasive spine surgery system, part of the BoShi Zeus Smart Minimally Invasive Surgery Platform, as an example, this system addresses critical pain points in minimally invasive spine procedures—such as prolonged time required for establishing surgical access channels, high radiation exposure, elevated risk levels, and intraoperative disorientation regarding instrument positioning and anatomical identification—which often leave physicians unable or reluctant to perform these surgeries. It provides a digital solution that assists surgeons in performing procedures through digital visualization without altering existing clinical workflows. This approach significantly reduces radiation exposure, enhances surgical efficiency, facilitates the widespread adoption of this technique, and lowers the learning curve for physicians. Consequently, it effectively promotes the decentralization of medical resources, benefiting both healthcare providers and patients.

Case Name:Haizheng Cloud - Digital Healthcare Regulatory Service Platform

Selected Institutions:Haihu Health (Shandong) Group Co., Ltd.

Application Subfields/Departments/Diseases:Regulation of Internet Hospitals, Regulation of Digital Therapeutics, and Regulation of “Internet + Nursing” Services

Annual Innovation Achievements and Outcomes:

Haizheng Cloud – Digital Healthcare Regulatory Service PlatformTo address inconsistencies in master data—such as hospital medications, laboratory tests, and examinations—as well as the diversity of medical terminology, we have leveraged natural language processing (NLP) and medical knowledge graph technologies to achieve data standardization. This approach not only resolves the issue of multiple codes for a single item and enhances the accuracy of statistical data, but also provides standardized medical terminology for data analysis. The platform is at the forefront among internet healthcare regulatory platforms across China’s provinces. It was recognized as an Industry Excellent System in 2023. Currently, its system and operational model are being replicated in regions such as Jiangxi and Yinchuan. It already supports the daily regulatory oversight of more than 400 internet hospitals throughout Shandong Province, playing a positive role in the development and regulation of local internet healthcare. The Shandong Provincial Internet Healthcare Regulatory Service Platform was custom-developed in strict compliance with national internet healthcare regulatory policies, based on a thorough interpretation and breakdown of these requirements.

Case Name:Jingyi Qianxun Large Language Model

Selected Institutions:JD Health (6618.HK)

Application Subfields/Departments/Disease Types:Medical Imaging Analysis, Clinical Text Processing, Multimodal Data Processing

Annual Innovation Achievements and Results:

Case Name:Intelligent Ultrasound Screening Device for Cardiovascular and Cerebrovascular Diseases

Selected Institutions:Lingshu Medical Technology (Suzhou) Co., Ltd.

Collaborating Organizations:Institute of Automation, Chinese Academy of Sciences

Application Subfields/Departments/Diseases:Primary Care, Cardiology Department, Physical Examination Center, Elderly Care Nursing Home

Annual Innovation Performance and Achievements:

Intelligent Ultrasound Screening System for Cardiovascular and Cerebrovascular Diseases integrates four core modules: autonomous scanning, 3D reconstruction, computer-aided diagnosis, and intelligent services, significantly enhancing screening efficiency and service capacity. Its portable desktop design, combined with a SCARA-like architecture, enables precise movement and adjustment of the ultrasound probe. The deployment of a cloud-edge-end collaborative service platform ensures real-time analysis of ultrasound images and efficient resource allocation. Cloud-based diagnostic algorithms and reporting modules support case management and statistical analysis. These innovations reduce costs and substantially improve the supply of ultrasound services and examination efficiency.

Cardiovascular and cerebrovascular diseases have become the leading cause of death among Chinese residents. To address the vast high-risk population, intelligent ultrasound screening devices for cardiovascular and cerebrovascular conditions can significantly improve screening efficiency. With one-click data acquisition, these devices leverage artificial intelligence to empower stroke and cardiovascular disease screening, and have already been deployed in healthcare institutions across multiple provinces in China. In 2023, as part of the Yangtze River Delta Medical-Prevention Integration Project in Tongling, Anhui Province, primary healthcare workers used these intelligent ultrasound screening devices to conduct stroke ultrasound screenings for 20,000 local residents, substantially enhancing the diagnostic capability and quality of primary healthcare services.

Currently, this case has spanned more than ten provinces and 48 cities across China, achieving widespread application in medical institutions at all levels and in various healthcare settings. It has benefited tens of thousands of residents in primary care communities, effectively advancing the in-depth implementation of cardiovascular and cerebrovascular disease screening, and significantly improving the accessibility and efficiency of ultrasound examinations.

Case Name:Digital Respiratory Chronic Disease Management System

Selected Institutions:Shenzhen Rongxin Medical Technology Co., Ltd.

Application Subfields/Departments/Diseases:Respiratory Sleep Health

Annual Innovation Achievements and Results:

The remote digital service model for chronic respiratory diseases, by introducing the ResAsist Digital Chronic Respiratory Disease Management System, achieves efficient screening, remote services, and personalized treatment for Obstructive Sleep Apnea Syndrome (OSAS). Leveraging big data, the Internet of Things (IoT), and artificial intelligence technologies, this platform significantly enhances medical service efficiency, enabling real-time upload of patient data and remote digital management. Multi-terminal access (smart devices, mini-programs, apps, and web interfaces) makes medical services more convenient, truly embodying the "patient-centered" service philosophy. This allows patients to enjoy comprehensive, personalized respiratory and sleep management services, significantly improving their service experience and treatment outcomes.

ResAsist Digital Respiratory Chronic Disease Management System delivers an unprecedented digital service experience by deeply integrating real-world patient data, artificial intelligence, and smart sleep apnea devices. Compared with other similar solutions, its key advantages lie in the deep integration of massive datasets with intelligent devices, broad regional applicability, significant industry potential for patients with obstructive sleep apnea syndrome (OSAS), and strong replicability and scalability in healthcare management.

Case Name:Intracardiac Echocardiography Imaging System

Selected Institutions:Shenzhen Saihe Medical Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Cardiovascular

Annual Innovation Achievements and Results:

Intracardiac Echocardiography (ICE) technology ingeniously combines phased-array ultrasound imaging with cardiac catheterization, providing an innovative ultrasound imaging solution for percutaneous vascular interventional procedures. Saihe Medical’s ICE system features DynaSight^®Composed of a single-use intracardiac echocardiography (ICE) imaging catheter and the UDG3900 series portable ultrasound diagnostic system, it utilizes a miniature phased-array transducer to continuously transmit and receive ultrasonic signals, enabling real-time, high-quality imaging of intracardiac anatomical structures, thereby serving as a critical imaging modality in interventional cardiology.

Saihe Medical’s independently developed domestic intracardiac echocardiography (ICE) system has garnered high recognition from experts in the DISTINCT clinical trial. Its overall performance, including catheter maneuverability and image quality, not only matches that of imported counterparts but even surpasses them in certain aspects. Notably, innovative technologies enable the system to achieve greater detection depth, making it suitable not only for routine cardiac interventional procedures but also for optimizing the workflow of ICE-guided left atrial appendage closure surgeries, significantly improving procedural efficiency and reducing complications. As the first domestically produced ICE system (comprising both catheter and console) to enter the innovation green channel and receive approval in China, Saihe Medical’s independently developed ICE system marks the rise of domestic intracardiac ultrasound technology.

Case Name:SupMR: AI-Based Medical Image Enhancement Product

Selected Institutions:Shenzhen Zhitou Medical Technology Development (Shanghai) Co., Ltd.

Application Subfields/Departments/Diseases:Medical Imaging

Annual Innovation Performance and Achievements:

SupMR leverages deep learning technology to accelerate MRI examinations and enhance image quality and resolution, enablingGenerative AIThe technology accelerates the MRI imaging process by 2–4 times, or reduces contrast agent usage by 90%, delivering superior image quality and diagnostic efficacy compared to pre-acceleration performance.

Through patented deep learning and generative AI model algorithms, SupMR enables healthcare institutions to examine more patients in less time while reducing radiation doses, thereby eliminating patient wait times. Furthermore, SupMR achieves seamless compatibility with various OEM scanners and PACS systems. This means that SupMR can be deployed as a SaaS solution without disrupting the daily workflows of radiologists—eliminating the need for costly hardware purchases and allowing for convenient, rapid software-based deployment in hospitals to optimize all clinical equipment.

Currently, Shenzhi Touyi’s SupMR has been implemented in clinical settings across markets in China, the United States, and Europe. It has been deployed in nearly 600 medical institutions and imaging centers worldwide, establishing collaborative partnerships with more than a dozen leading U.S. medical schools, hospitals, and third-party imaging centers, including Stanford University School of Medicine, UCSF, MD Anderson Cancer Center, and Mayo Clinic.Furthermore, DeepWise Medical has partnered with leading domestic and international equipment manufacturers, including Siemens Healthineers, Nanovision Imaging, and Regentech, to develop AI-enhanced platforms for their devices, thereby empowering them to achieve superior image quality.Furthermore, Shenzhitouyi has signed agreements with pharmaceutical companies such as Bracco and Bayer. Through close collaboration with globally renowned contrast media manufacturers, it drives the acceleration and optimization of contrast agent R&D, helping pharmaceutical companies achieve intelligent upgrades to their product portfolios and deliver safer, more effective enhanced medical imaging outcomes.

Case Name:Myopia Risk Factor Monitor

Selected Institutions:12mm Health Technology (Hainan) Co., Ltd.

Collaborating Organizations:Hainan Eye Hospital

Application Subfields/Departments/Diseases:Adolescent Myopia Prevention and Control

Annual Innovation Achievements and Outcomes:

Case Name:ShukunGPT Empowers the Full Lifecycle of Healthcare

Selected Institutions:Shukun Technology Co., Ltd.

Application Subfields/Departments/Diseases:AI Healthcare

Annual Innovation Achievements and Outcomes:

Shukun Technology’s self-developed multimodal medical large language model, ShukunGPT, leverages the company’s top-tier team integrating medical and engineering expertise and its original innovation capabilities. Trained efficiently on a high-quality medical data ecosystem, ShukunGPT possesses cross-modal and interdisciplinary capabilities, with an intelligence level comparable to that of mid-to-senior-level physicians. ShukunGPT assists doctors in efficiently completing diagnostic and treatment tasks, covering the entire patient lifecycle and full-course disease management, thereby comprehensively empowering healthcare and the broader health industry and leading new industrial paradigms. In the task of “large model-driven precise disease diagnosis,” it achieves a single-disease diagnostic accuracy of 98%, a multi-comorbidity diagnostic accuracy of 80%, and a twofold increase in diagnostic efficiency.

ShukunGPT was awarded first prize in the Beijing Industry Large Model Innovative Application Competition at the Zhongguancun Forum, standing as the sole winner in the medical field. It ranked first on the CMB, the world’s largest Chinese medical evaluation benchmark, achieving state-of-the-art (SOTA) scores, and its performance on medical licensing examinations far surpassed that of large models developed by international tech giants. Leveraging proprietary AI technologies and the integration of medicine and engineering, Shukun Technology is poised to address the scarcity of high-quality medical resources. By drawing on its experience in transforming radiology departments—outpacing international tech giants—and its robust medical AI R&D capabilities, Shukun aims to expand AI applications from radiology to all clinical departments, extending empowerment from within hospitals to outside settings, thereby establishing a closed-loop system for healthcare management.

Case Name:Liu Liu Brain Cognitive Impairment Digital Therapeutics

Selected Institutions:Zhejiang Brain Aurora Medical Technology Co., Ltd.

Application Subfields/Departments/Diseases:Cognitive Impairment

Annual Innovation Achievements and Outcomes:

Liu Liu Nao’s digital therapeutic for cognitive impairment focuses on providing comprehensive health management services to patients with cognitive disorders. This case ingeniously integrates brain science, medicine, and artificial intelligence technologies. Through an internet-based digital therapeutic platform, it achieves comprehensive screening, precise assessment, effective rehabilitation, and continuous monitoring of cognitive impairment. Its application at renowned institutions such as Xuanwu Hospital of Capital Medical University and Beijing Anzhen Hospital fully demonstrates its significant efficacy in the medical field and its substantial potential for widespread adoption.

The innovation of this case lies in the development of cognitive function assessment tools tailored to the characteristics of the local population, thereby enhancing the relevance and accuracy of assessments. By leveraging big data and artificial intelligence technologies, intelligent digital therapeutics enable personalized cognitive function assessment and training protocols, significantly improving the precision of rehabilitation training and patient experience. Furthermore, the case provides end-to-end services spanning health monitoring, physical examinations, and disease management, establishing a three-tier chronic disease management system linking hospitals, communities, and households. Through collaborations with multiple medical institutions, research findings are rapidly translated into clinical applications, promoting the standardization and normalization of diagnosis and treatment for cognitive disorders. Meanwhile, a specialized talent training system for cognitive disorders and a direct data reporting system have been established, enhancing the efficiency of medical services and the accuracy of research data.